Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Masakazu, Yamaguchi"'
Autor:
Kenichi Suzuki, Takashi Yokokawa, Takashi Kawaguchi, Shinya Takada, Shinya Tamaki, Yohei Kawasaki, Takumi Yamaguchi, Kei Koizumi, Takuma Matsumoto, Yukio Sakata, Yuichiro Arakawa, Hideaki Ayuhara, Mari Hosonaga, Masakazu Yamaguchi, Daiki Tsuji
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Dexamethasone is an antiemetic drug widely used to prevent nausea and vomiting caused by anticancer drugs. However, dexamethasone can cause several side effects even after short-term administration. Therefore, the development of dexamethason
Externí odkaz:
https://doaj.org/article/53735ad51c704d818a926890c2148e15
Autor:
Takashi Yokokawa, Kenichi Suzuki, Daiki Tsuji, Mari Hosonaga, Kazuo Kobayashi, Kazuyoshi Kawakami, Hitoshi Kawazoe, Tomonori Nakamura, Wataru Suzuki, Takahito Sugisaki, Takeshi Aoyama, Koki Hashimoto, Masahiro Hatori, Takuya Tomomatsu, Ayaka Inoue, Keiichi Azuma, Maimi Asano, Toshimi Takano, Shinji Ohno, Masakazu Yamaguchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18745-18754 (2023)
Abstract Background Female sex and younger age are reported risk factors for chemotherapy‐induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to c
Externí odkaz:
https://doaj.org/article/8cf3b7f0b5934cada3416f1a0aaf9b60
Autor:
Daisuke Ueki, Shinya Suzuki, Takahiro Ohta, Akira Shinohara, Yasukata Ohashi, Daisuke Konuma, Yasuaki Ryushima, Ryoko Udagawa, Hironori Motoshige, Masahiro Ieoka, Akihiro Taji, Yuuki Kogure, Mikako Hiraike, Miyuki Uoi, Kazuhiko Ino, Toshikatsu Kawasaki, Masakazu Yamaguchi
Publikováno v:
Pharmacy, Vol 12, Iss 1, p 1 (2023)
Although prescription review is an important role for pharmacists in anticancer drug therapy, there are no guidelines in Japan that specify what pharmacists should check for in chemotherapy regimens. This prospective multicenter survey aimed to inves
Externí odkaz:
https://doaj.org/article/affda06035f2417e91f2adfbc852a57e
Autor:
Yoshiko Kitazume, Hitoshi Kawazoe, Ryuji Uozumi, Tomoe Yoshizawa, Hirotoshi Iihara, Hironori Fujii, Masaya Takahashi, Takahiro Arai, Yasushi Murachi, Yumiko Sato, Takahiro Mikami, Koji Hashiguchi, Tomoko Yamazaki, Katsuyuki Takahashi, Yukiyoshi Fujita, Yuki Hosokawa, Issei Morozumi, Masami Tsuchiya, Atsushi Yokoyama, Hironobu Hashimoto, Masakazu Yamaguchi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract The association between capecitabine efficacy and proton pump inhibitors (PPIs) is controversial. Here, we determined whether co-administration of PPIs affects the real-world effectiveness of capecitabine. This retrospective observational st
Externí odkaz:
https://doaj.org/article/96f14db77f724404b2128c9eb38030de
Autor:
Yoshikazu Tateai, Kazuyoshi Kawakami, Minori Teramae, Naoki Fukuda, Takashi Yokokawa, Kazuo Kobayashi, Naoki Shibata, Wataru Suzuki, Hisanori Shimizu, Shunji Takahashi, Masato Ozaka, Naoki Sasahira, Satoko Hori, Masakazu Yamaguchi
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0294320 (2023)
BackgroundLenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and to identify factors ass
Externí odkaz:
https://doaj.org/article/b4c46abab72a478f8786e1e944661312
Autor:
Toshiki Ogiwara, Hitoshi Kawazoe, Saeka Egami, Hironobu Hashimoto, Yoshimasa Saito, Naomi Sakiyama, Yuichiro Ohe, Masakazu Yamaguchi, Tetsuya Furukawa, Azusa Hara, Yui Hiraga, Aya Jibiki, Yuta Yokoyama, Sayo Suzuki, Tomonori Nakamura
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundNivolumab and pembrolizumab are the standard treatments for patients with advanced non-small-cell lung cancer (NSCLC). While there are reports on several inflammatory indices and the prognosis of patients with cancer, no study has combined
Externí odkaz:
https://doaj.org/article/b197c72349844806ab490770dcad20f3
Publikováno v:
BMJ case reports. 14(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf225fcfe31d36145eaf6cdd4929e2f1
https://pubmed.ncbi.nlm.nih.gov/34969815
https://pubmed.ncbi.nlm.nih.gov/34969815
Autor:
Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura, Koichi Fukunaga, Masakazu Yamaguchi, Tomonori Nakamura
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundAmong patients with advanced non-small-cell lung cancer who were treated with nivolumab monotherapy, the association of peripheral blood count data (at baseline and 2 weeks after treatment initiation) with the early onset of immune-related
Externí odkaz:
https://doaj.org/article/ebbfc82a076b46618759914ca36dd8ef
Autor:
Shinya Suzuki, Ai Horinouchi, Shinya Uozumi, Chihiro Matsuyama, Hayato Kamata, Asumi Kaneko, Masakazu Yamaguchi, Hiroshi Okudera, Makoto Tahara, Toshikatsu Kawasaki
Publikováno v:
SAGE Open Medicine, Vol 8 (2020)
Objectives: Medical oncologists and pharmacists at our institution established an integrated support program aimed at preventing unnecessary treatment interruption or dose reduction during oral targeted therapy with lenvatinib. Here, we evaluated the
Externí odkaz:
https://doaj.org/article/b6fbe7c9ad4f499f8cd07c2f5f6e0596
Autor:
Shinya Uozumi, Tomohiro Enokida, Shinya Suzuki, Aya Nishizawa, Hayato Kamata, Tomoka Okano, Takao Fujisawa, Yuri Ueda, Susumu Okano, Makoto Tahara, Masakazu Yamaguchi
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Background: Skin toxicity is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the correlation between skin toxicity and the efficacy of Cmab in patients with recurrent or metastatic squamous cell carcin
Externí odkaz:
https://doaj.org/article/ed897b7ae5e84a0dad2f60b6b50b3f76